Conivaptan
- Generic Name
- Conivaptan
- Brand Names
- Vaprisol
- Drug Type
- Small Molecule
- Chemical Formula
- C32H26N4O2
- CAS Number
- 210101-16-9
- Unique Ingredient Identifier
- 0NJ98Y462X
- Background
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
- Indication
For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
- Associated Conditions
- Euvolemic Hyponatremia, Hypervolemic Hyponatremia
- Associated Therapies
- -
A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
- Conditions
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT00435591
An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 251
- Registration Number
- NCT00379847
- Locations
- 🇿🇦
2 Sites, Durban, South Africa
🇿🇦4 Sites, Johannesburg, South Africa
Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure
- First Posted Date
- 2003-04-01
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 170
- Registration Number
- NCT00057356
- Locations
- 🇺🇸
Ohio State University Medical Center, Heart and Lung Research Institute, Columbus, Ohio, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸The Heart Center, P.C., Huntsville, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.